Targeted therapies: Cetuximab plus chemotherapy in patients with advanced NSCLC

Nat Rev Clin Oncol. 2009 Sep;6(9):499-500. doi: 10.1038/nrclinonc.2009.108.
No abstract available

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Agents, Phytogenic / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Cetuximab
  • Cisplatin / administration & dosage
  • Clinical Trials, Phase III as Topic
  • Dose-Response Relationship, Drug
  • Epidermal Growth Factor / metabolism
  • ErbB Receptors / antagonists & inhibitors
  • Follow-Up Studies
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Proportional Hazards Models
  • Survival Analysis
  • Time Factors
  • Treatment Outcome
  • Vinblastine / administration & dosage
  • Vinblastine / analogs & derivatives
  • Vinorelbine

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Antineoplastic Agents, Phytogenic
  • Vinblastine
  • Epidermal Growth Factor
  • ErbB Receptors
  • Cetuximab
  • Cisplatin
  • Vinorelbine